32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma

Abstract Background Treatment of hepatocellular carcinoma (HCC) using antibody-based targeted therapies, such as antibody conjugates and chimeric antigen receptor T (CAR-T) cell therapy, shows potent antitumor efficacy. Glypican-3 (GPC3) is an emerging HCC therapeutic target; therefore, antibodies a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaoyu Liu, Fang Gao, Longwei Jiang, Meng Jia, Lei Ao, Ming Lu, Liming Gou, Mitchell Ho, Shaochang Jia, Fei Chen, Wei Gao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-08-01
coleção:	Journal of Translational Medicine
Assuntos:	Liver cancer Glypican-3 Antibody Immunotoxin Chimeric antigen receptor
Acesso em linha:	http://link.springer.com/article/10.1186/s12967-020-02462-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!